Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens?
Tuesday, December 7, 2010 - 14:31
in Health & Medicine
Researchers analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) -- which led to the FDA approval of pralatrexate in September 2009. Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.